FRANKLIN, Mass., Oct. 16 /PRNewswire-FirstCall/ -- Echo Therapeutics
(OTC Bulletin Board: ECTE) announced the issuance of U.S. Patent 7,432,069
covering compositions and methods for the preparation of a polyethylene
glycol (PEG)-based hydrogel as a key component of Echo's Symphony(TM)
Transdermal Continuous Glucose Monitoring (tCGM) System.

    "Our proprietary PEG hydrogel, specifically designed to enable
transdermal biosensing, is characterized by excellent stability,
sensitivity, integrity and biocompatibility, making our Symphony tCGM
System a desirable system for non-invasive continuous glucose monitoring,"
stated Patrick Mooney, M.D., Echo's Chairman and CEO. "This patent is
critical to our intellectual property strategy for protecting our leading
position in non-invasive, tCGM markets worldwide."

    Echo's Symphony(TM) tCGM System is in late-stage development for both
the diabetes home use and hospital critical care settings. Symphony
incorporates Echo's new Prelude(TM) SkinPrep System with patented,
leading-edge skin permeation control technologies.

    About Echo Therapeutics

    Echo Therapeutics is focused on late-stage development of transdermal
diagnostic devices and specialty pharmaceuticals. Echo is developing a
non-invasive (needle-free), transdermal continuous glucose monitoring
system together with novel transdermal reformulations of existing
FDA-approved products.

    Forward Looking Statements

    Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and uncertainties. The
factors that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks related to
regulatory approvals and the success of Echo's ongoing clinical studies
regarding the efficacy of its Symphony tCGM System, the failure of future
development and preliminary marketing efforts related to Echo's tCGM
System, risks and uncertainties relating to Echo's ability to develop,
market and sell diagnostic products based on its skin permeation platform
technologies, including the Prelude SkinPrep System, the availability of
substantial additional equity or debt capital to support its research,
development and product commercialization activities, and the success of
its research, development, and regulatory approval, marketing and
distribution plans and strategies, including those plans and strategies
related to its Symphony tCGM System. These and other factors are identified
and described in more detail in Echo's filings with the Securities and
Exchange Commission, including, without limitation, its annual report on
Form 10-KSB for the year ended December 31, 2007, its quarterly reports on
Form 10-Q, and its current reports on Form 8-K. The foregoing list of
factors is not exhaustive. Echo Therapeutics, Inc. undertakes no obligation
to publicly update or revise any forward-looking statements.



    Investor Relations Contacts:

    Patrick T. Mooney, M.D.
    Chairman and CEO
    Echo Therapeutics
    508-530-0329

    Melanie Friedman
    Stern Investor Relations
    212-362-1200

Link to this page: